Floatz logo

NKG2D CAR-NK

Refractory Metastatic Colorectal Cancer

Zhejiang UniversityCell therapyPhase 1Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
95/ 100

Competitive context

839 Active assets in the Refractory Metastatic Colorectal Cancer cohort.

Asset / SponsorPhaseRating
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
MARBLE DUST
James Varani
Phase 2/3BB
Cetuximab
Shanghai Henlius Biotech
Phase 4BB
FLUOROURACILUM
Washington University School of Medicine
Phase 4BB
PANITUMUMAB
M.D. Anderson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

NKG2D CAR-NK is also rated in:

metastatic malignant neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
acute myeloid leukemiaDormant
D
Indicative ·
30 / 100
View asset →
ovarian cancerDormant
D
Indicative ·
26 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →